Chrysafis AndreouVolker NeuschmeltingDarjus-Felix TschaharganehChun‐Hao HuangAnton OseledchykPasquale IaconoHazem KarabeberRivka R. ColenLorenzo MannelliScott W. LoweMoritz F. Kircher
Complete surgical resection is the ideal first-line treatment for most liver malignancies. This goal would be facilitated by an intraoperative imaging method that enables more precise visualization of tumor margins and detection of otherwise invisible microscopic lesions. To this end, we synthesized silica-encapsulated surface-enhanced Raman scattering (SERS) nanoparticles (NPs) that act as a molecular imaging agent for liver malignancies. We hypothesized that, after intravenous administration, SERS NPs would avidly home to healthy liver tissue but not to intrahepatic malignancies. We tested these SERS NPs in genetically engineered mouse models of hepatocellular carcinoma and histiocytic sarcoma. After intravenous injection, liver tumors in both models were readily identifiable with Raman imaging. In addition, Raman imaging using SERS NPs enabled detection of microscopic lesions in liver and spleen. We compared the performance of SERS NPs to fluorescence imaging using indocyanine green (ICG). We found that SERS NPs delineate tumors more accurately and are less susceptible to photobleaching. Given the known advantages of SERS imaging, namely, high sensitivity and specific spectroscopic detection, these findings hold promise for improved resection of liver cancer.
Stefan HarmsenMatthew A. WallRuimin HuangMoritz F. Kircher
Chrysafis Andreou (1890958)Volker Neuschmelting (2733988)Darjus-Felix Tschaharganeh (2733982)Chun-Hao Huang (189684)Anton Oseledchyk (2733979)Pasquale Iacono (1341210)Hazem Karabeber (1341216)Rivka R. Colen (145280)Lorenzo Mannelli (652500)Scott W. Lowe (104375)Moritz F. Kircher (1316520)
Altaf KhetaniAli MomenpourVidhu S. TiwariHanan Anis
Yong Il KimSinyoung JeongBong‐Hyun JunYun‐Sang LeeYoon-Sik LeeDae Hong JeongDong Soo Lee